YK‑11 (Myostatin Inhibitor SARM)
Experimental steroid-like SARM compound studied only in cells and rats, not proven in humans; may strain the liver.


The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

DETAILED OVERVIEW
What is YK-11 (Myostatin Inhibitor SARM)?
YK-11 is an experimental compound classed as a SARM: a substance that binds to the same receptors as testosterone. Unlike the usual SARMs, its structure resembles a steroid. It has never been approved as a medicine, it is sold on the black market as a research chemical, and it is banned in competitive sport all year round.
In cell experiments it switched on the testosterone receptor and at the same time raised the level of a protein that blocks myostatin, the body's natural brake on muscle growth. It has not been tested in humans, only in the lab and in rats, and a later lab study questioned whether the effect is large enough. Because of its steroid-like structure, a risk to the liver similar to that of steroids taken by mouth is expected, and two cases of liver damage linked to it have been described. It is expected to worsen cholesterol values and may shut down the body's own testosterone production. It must not be used by women or in pregnancy, because it can cause masculinization and harm to the fetus; together with alcohol the strain on the liver grows.
Mechanism
Steroidal SARM (5α-androstane scaffold) + myostatin pathway inhibitor (follistatin upregulation)
Clinical precedent
Phase 0 in vitro only (Kanno 2011/2013, Yatsu 2018). No Phase I/II/III in humans.
Anabolic activity
AR binding ~50% testosterone (in vitro) + myostatin block dual effect
Half-life
~6-10 h (oral, estimated)
Legal status
Never an Rx. UGL 'research chemical'. WADA-banned S1.2.
Anecdotal reports describe YK-11 as producing rapid increases in muscle fullness, strength, glycogen storage, aggression, and overall visual density. The compound's follistatin-upregulating effect is credited with much of the muscle growth users see. Many community accounts describe YK-11 as functioning more like a dry oral anabolic than a typical SARM, with a distinctly dry visual signature. Reported adverse effects include aggression, insomnia, irritability, and libido fluctuations. The 'myostatin inhibitor' label commonly applied to YK-11 is mechanistically imprecise – true pharmaceutical-grade myostatin inhibition requires monoclonal antibodies or gene-targeting therapy. YK-11 does not directly inhibit myostatin; rather, it appears to influence the pathway via follistatin upregulation. Overall, community accounts report fast size and strength gains and notable potency for a SARM, while also flagging meaningful theoretical and clinical concerns – including 17α-steroid-like hepatotoxicity profile and HPTA suppression. Do your own research.
⚠ Not clinical evidence – based on user accounts.
Data console
Lab data
Kanno Y, Ota R, Someya K, Bochimoto H, Kondo S, Inouye Y . Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression.. Biol Pharm Bull.
Vajda EG, López FJ, Rix P, Hermann R, Allan G . Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator.. J Pharmacol Exp Ther.
Labban H, Kwait B, Paracha A, Khan A, Singh M, Lopez R . LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults.. Cureus.
Leciejewska N, Jędrejko K, Gómez-Renaud VM, Manríquez-Núñez J, Muszyńska B, Pokrywka A . Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases.. Eur J Clin Pharmacol.
Lee SJ . Myostatin: A Skeletal Muscle Chalone.. Annu Rev Physiol.
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Hepatotoxicity (liver injury): the 17alpha-methoxycarbonyl steroidal scaffold gives a profile similar to 17alpha-alkylated oral AAS, with ALT/AST elevation and documented SARM-associated drug-induced liver injury (DILI) cases.
- HPTA suppression: suppression of endogenous testosterone production (reduced LH/FSH), which can cause lowered libido, fatigue and post-cycle hypogonadism, requiring PCT.
- Adverse lipid profile: marked drop in HDL (good cholesterol), typical of oral androgenic compounds, increasing cardiovascular risk.
- Androgenic side effects: per anecdotal reports, acne, increased oiliness and possible hair loss in androgen-sensitive individuals (due to AR-agonist activity).
- Neuropsychiatric effects: anecdotal user reports of aggression, irritability, insomnia and libido fluctuations.
- No water retention / dry effect: it does not aromatize (Delta-4,9-triene configuration), so there is no estrogen-mediated water retention, though the dryness may anecdotally cause joint discomfort.
- Adulteration / contamination risk: on the gray market it is often substituted with or contaminated by methylstenbolone (a cheaper 17alpha-methyl prohormone), causing different and unpredictable toxicity. An HPLC-tested source is mandatory.
Contraindications · 7
- Pregnancy, breastfeeding and women in general: due to AR-agonist activity, risk of potentially irreversible virilization (voice deepening, hirsutism) and fetal harm; strongly contraindicated in women of childbearing age.
- Pre-existing liver dysfunction or elevated ALT/AST: absolute contraindication given the steroidal hepatotoxicity, when baseline liver values are raised.
- Concurrent alcohol use or other hepatotoxic agents: risk of cumulative liver injury; alcohol and other liver-burdening drugs should be avoided during the cycle.
- Stacking with other SARMs or 17alpha-alkylated oral AAS: not advised due to cumulative hepatotoxicity and lipid toxicity.
- Planned fatherhood / fertility concerns: HPTA suppression can temporarily impair spermatogenesis, with full recovery taking up to 3-6 months.
- Competitive athletes: banned year-round by WADA (S1.2, other anabolic agents), detectable in urine for 3-5 weeks; will cause an anti-doping violation.
- Pre-existing cardiovascular disease or dyslipidemia: the marked HDL drop can further worsen the lipid profile and raise cardiovascular risk.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression.
Kanno Y, Ota R, Someya K, Bochimoto H, Kondo S, Inouye Y
Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator.
Vajda EG, López FJ, Rix P, Hermann R, Allan G
LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults.
Labban H, Kwait B, Paracha A, Khan A, Singh M, Lopez R
Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases.
Leciejewska N, Jędrejko K, Gómez-Renaud VM, Manríquez-Núñez J, Muszyńska B, Pokrywka A
Myostatin: A Skeletal Muscle Chalone.
Lee SJ
Telegram
Have a question about YK‑11 (Myostatin Inhibitor SARM)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.